Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 844 results for "gilead sciences"

Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Resources, Gilead Sciences, Apple, and Plug Power
Nasdaq

Earnings Forecast Report for Yahoo, Alibaba, Cliffs Natural Re...

PHOENIX, Nov. 20, 2014 /PRNewswire/ -- EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Yahoo! (NASDAQ:YHOO), Alibaba (NYSE:BABA), Cliffs Natural Resources (NYSE:CLF), ... TickerTech.com, 14 hours ago
[x]  

95 images for gilead sciences

InvestorPlace.com, 2 days ago
American Banking News, 1 week ago
InsiderMonkey.com, 4 days ago
Brisbane Times, 2 days ago
CNBC, 1 week ago
Value Walk, 1 week ago
Azerbaijan News.Net, 1 week ago
Jutia Group, 1 week ago
Bidness Etc, 17 hours ago
Bidness Etc, 1 day ago
Bidness Etc

Gilead's once daily tablet regimen, Harvoni gets European marketing nod to treat HCV with genotype 1 & 4

The European Commission has granted marketing authorization for Gilead Sciences' Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in ...
 PharmaBiz1 day ago Commission approves ledipasvir/sofosbuvir combo for marketing in EU  Orthopedics Today5 hours ago Harvoni Cures Almost All People With Hep C Coinfected With HIV  AIDSmeds8 hours ago Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni  TheStreet.com2 days ago
[x]  

France gets larger discount on Sovaldi than its neighbors

France's hard line negotiations with Gilead Sciences (GILD -0.1%) over Sovaldi (sofosbuvir) pricing paid off. The agreed-upon price per box will be €13,667 which is €5,000 lower than the original price. The full 12-week regimen cost will be ...
 Seeking Alpha11 hours ago France pegs Gilead hepatitis C drug at "lowest price in Europe"  Yahoo! Finance15 hours ago France negotiates lowest price in Europe for Gilead Sciences Sovaldi  FirstWord Pharma6 hours ago 2014: Gilead raking in massive cash from hepatitis C drug Sovaldi  SiliconValley.com1 day ago
[x]  

Gilead to Buy Knight Therapeutics' Priority Review Voucher

Gilead Sciences, Inc. ( GILD ) has entered into an agreement to purchase neglected tropical disease priority review voucher from Canada based Knight Therapeutics Inc. On completion of the transaction, Gilead will pay $125 million to Knight ...
 Yahoo! Finance7 hours ago
Bidness Etc

Gilead Sciences (GILD) Sets Record By Paying $125 Million For An FDA Priority Review Voucher

In a move unheard of in the industry, Gilead agreed to pay $125 million to a small Canadian drug maker for an FDA priority review voucher for tropical diseases Page 1 of 2 Click Ticker to See live coverage Gilead Sciences, Inc. ( ...
 Bidness Etc17 hours ago Gilead buys FDA voucher for $125M  Seeking Alpha1 day ago With Gilead's $125M Purchase, FDA Voucher Program Gains Momentum  Xconomy1 day ago Gilead Buys Shortcut For FDA Drug Review For $125 Million  NPR1 day ago
[x]  

Lowest PEG Ratio in the Biotechnology Industry Detected in Shares of Gilead Sciences (GILD, ANIK, ACOR, ALXN, CBST)

(Comtex SmarTrend(R)) Below are the three companies in the Biotechnology industry with the lowest price to earnings to growth (PEG) ratios. PEG is valuable in assessing the tradeoff between the price of a stock and expected growth. Generally, the ...
 Individual.com16 hours ago

Gilead announces favorable results from Phase II and Phase III HCV studies

Gilead Sciences, Inc., a biotechnology company, has announced favorable results from several Phase II and Phase III studies evaluating investigational uses of Harvoni for the treatment of chronic hepatitis C virus, or HCV, infection in patients with ...
 Individual.com1 day ago Gilead announces encouraging data from Phase II HCV infection studies  Individual.com1 day ago

Gilead Gains on Harvoni's EU Approval for HCV Treatment

Shares of Gilead Sciences Inc. ( GILD ) were up 3.3% after the company announced that its hepatitis C virus (:HCV) drug, Harvoni, gained approval from the European Commission for treating adults suffering from chronic hepatitis C genotype 1 and 4 ...
 Yahoo! Finance1 day ago
Seeking Alpha

Gilead: Rising Net Income, Zero Debt And Strong R&D Pipeline

Summary Sovaldi carries Gilead to a blowout quarter with net income up 246%. Gilead Sciences board of directors approved a $5 billion share repurchase program on May 7, 2014. Rich R&D pipeline of 27 new drugs. Gilead Sciences, Inc. (NASDAQ: ...
 Seeking Alpha1 day ago

Gilead Sciences submits NDA for HIV drug to FDA

Gilead Sciences, Inc., a biotechnology company, has submitted a new drug application, or NDA, to the FDA for an investigational, once-daily single tablet regimen containing elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir ...
 Individual.com1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - gilead sciences
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less